Spero R Cataland

List of Publications by Citations

115 papers	2,994 citations	30 h-index	53 g-index
119 ext. papers	3,877 ext. citations	5.7 avg, IF	5.35 L-index

#	Paper	IF	Citations
115	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. *New England Journal of Medicine*, **2019**, 380, 335-346	59.2	337
114	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. *New England Journal of Medicine*, **2016**, 374, 511-22	59.2	322
113	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. *Blood*, **2003**, 101, 425-32	2.2	196
112	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. *American Journal of Kidney Diseases*, **2016**, 68, 84-93	7.4	162
111	Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. *Blood*, **2014**, 123, 3733-8	2.2	112
110	How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. *Blood*, **2014**, 123, 2478-84	2.2	96
109	Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. *Haematologica*, **2010**, 95, 1555-62	6.6	95
108	Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. *British Journal of Haematology*, **2008**, 141, 651-8	4.5	94
107	Venous thromboembolic disease. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 1402-29	7.3	73
106	A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. *Clinical Cancer Research*, **2008**, 14, 2444-9	12.9	71
105	An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. *British Journal of Haematology*, **2007**, 136, 146-9	4.5	64
104	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2012**, 87, 430-2	7.1	59
103	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2496-2502	15.4	57
102	None of the above: thrombotic microangiopathy beyond TTP and HUS. *Blood*, **2017**, 129, 2857-2863	2.2	55
101	Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. *American Journal of Clinical Pathology*, **2015**, 143, 558-65	1.9	50
100	Myeloid growth factors. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 1266-90	7.3	49
99	Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. *British Journal of Haematology*, **2007**, 139, 486-93	4.5	49

98	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. *Kidney International*, **2020**, 97, 1287-1296	9.9	43
97	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2011**, 86, 87-9	7.1	41
96	Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. *Blood Advances*, **2017**, 1, 2075-2082	7.8	39
95	Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. *New England Journal of Medicine*, **2019**, 381, 92-94	59.2	38
94	Diagnosis and management of complement mediated thrombotic microangiopathies. *Blood Reviews*, **2014**, 28, 67-74	11.1	36
93	The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. *British Journal of Haematology*, **2012**, 157, 501-3	4.5	36
92	Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1925-7	15.4	36
91	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2486-2495	15.4	36
90	Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. *Haematologica*, **2006**, 91, 1329-35	6.6	36
89	Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. *European Journal of Internal Medicine*, **2013**, 24, 486-91	3.9	35
88	The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. *Blood*, **2018**, 132, 903-910	2.2	34
87	Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2008**, 83, 911-5	7.1	34
86	Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. *Annals of Hematology*, **2013**, 92, 845-6	3	32
85	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. *Blood Advances*, **2018**, 2, 2619-2628	7.8	30
84	Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. *Transfusion*, **2015**, 55, 18-24	2.9	29
83	Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. *American Journal of Hematology*, **2010**, 85, 976-7	7.1	28
82	Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 479-484	15.4	28
81	Redefining outcomes in immune TTP: an international working group consensus report. *Blood*, **2021**, 137, 1855-1861	2.2	28

80	ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. *Haematologica*, **2011**, 96, 1521-7	6.6	23
79	Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. *European Journal of Haematology*, **2009**, 83, 559-64	3.8	23
78	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood*, **2020**, 136, 2103-2117	2.2	23
77	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. *Journal of Clinical Medicine*, **2021**, 10,	5.1	23
76	Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. *Kidney International Reports*, **2019**, 4, 1568-1576	4.1	21
75	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. *Thrombosis Research*, **2017**, 151, 51-56	8.2	19
74	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. *Intensive Care Medicine*, **2019**, 45, 1518-1539	14.5	19
73	Immunotherapy for thrombotic thrombocytopenic purpura. *Current Opinion in Hematology*, **2005**, 12, 359-63	3.3	18
72	Novel therapies in thrombotic thrombocytopenic purpura. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 19-26	5.1	17
71	Profound neurological injury in a patient with atypical hemolytic uremic syndrome. *Annals of Hematology*, **2013**, 92, 557-8	3	17
70	ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. *British Journal of Haematology*, **2011**, 153, 277-9	4.5	15
69	TTP disease course is independent of myeloma treatment and response. *American Journal of Hematology*, **2010**, 85, 304-6	7.1	15
68	Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. *American Journal of Hematology*, **2020**, 95, E76-E77	7.1	13
67	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. *Clinical Colorectal Cancer*, **2016**,	3.8	12
66	Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2001**, 41, 297-307	1.9	12
65	Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. *British Journal of Haematology*, **2010**, 149, 623-5	4.5	11
64	Eculizumab deposits in vessel walls in thrombotic microangiopathy. *Kidney International*, **2019**, 96, 761-768	9.9	10
63	Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).. *Blood*, **2005**, 106, 145-145	2.2	9

62	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2503-2512	15.4	9
61	Headache prevalence following recovery from TTP and aHUS. *Annals of Hematology*, **2015**, 94, 1473-6	3	7
60	Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. *Thrombosis and Haemostasis*, **2010**, 103, 1203-9	7	7
59	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. *Kidney International Reports*, **2021**, 6, 1603-1613	4.1	7
58	No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry. *American Journal of Hematology*, **2018**, 93, E73-E75	7.1	7
57	Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura. *Seminars in Hematology*, **2011**, 48, 242-50	4	6
56	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. *Blood*, **2017**, 130, LBA-1-LBA-1	2.2	6
55	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. *Blood Advances*, **2021**, 5, 2137-2141	7.8	6
54	Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. *Blood*, **2019**, 134, 1099-1099	2.2	5
53	Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. *Journal of Oncology Pharmacy Practice*, **2019**, 25, 567-576	1.7	5
52	Cardiovascular Disease is a Leading Cause of Mortality among TTP Survivors in Clinical Remission. *Blood Advances*, **2021**,	7.8	5
51	Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. *European Heart Journal - Case Reports*, **2020**, 4, 1-6	0.9	4
50	Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. *Kidney International Reports*, **2020**, 5, 1161-1171	4.1	4
49	Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. *Case Reports in Hematology*, **2015**, 2015, 327980	0.7	4
48	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. *Cancer Chemotherapy and Pharmacology*, **2010**, 65, 319-24	3.5	4
47	Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 437-44	4	4
46	Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors. *Blood*, **2020**, 136, 22-23	2.2	4
45	Antibody therapy of acute and chronic leukemias. *Current Pharmaceutical Biotechnology*, **2001**, 2, 357-67	2.6	4

44	Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura. *British Journal of Haematology*, **2020**, 189, e18-e20	4.5	3
43	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. *Blood*, **2018**, 132, 3739-3739	2.2	3
42	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. *Blood*, **2018**, 132, 1142-1142	2.2	3
41	A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. *Blood*, **2016**, 128, 133-133	2.2	3
40	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. *Blood*, **2018**, 132, 373-373	2.2	2
39	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. *Blood*, **2018**, 132, 3744-3744	2.2	2
38	Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS). *Blood*, **2013**, 122, 2179-2179	2.2	2
37	SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. *Nephrology Dialysis Transplantation*, **2020**, 35,	4.3	2
36	Eculizumab therapy. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 438-9	4.7	1
35	3 Rs: rituximab, remission, relapse. *Blood*, **2011**, 118, 1711-2	2.2	1
34	Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12658	5.1	1
33	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. *Blood*, **2019**, 134, 4908-4908	2.2	1
32	Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy. *Blood*, **2019**, 134, 1098-1098	2.2	1
31	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. *Blood*, **2019**, 134, 90-90	2.2	1
30	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. *Blood*, **2019**, 134, 931-931	2.2	1
29	Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review. *Blood*, **2015**, 126, 2189-2189	2.2	1
28	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. *Bone Marrow Transplantation*, **2019**, 54, 913-916	4.4	1
27	FP250FACIT-FATIGUE SCORES IN ADULT PATIENTS AT ENROLLMENT INTO THE GLOBAL AHUS REGISTRY. *Nephrology Dialysis Transplantation*, **2018**, 33, i114-i114	4.3	1

26	Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2021**, 96, 1587-1594	7.1	1
25	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. *Blood*, **2019**, 134, 2365-2365	2.2	0
24	In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests. *Journal of the American Academy of Dermatology*, **2021**, 85, 301-310	4.5	0
23	Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies. *British Journal of Haematology*, **2014**, 167, 697-8	4.5	
22	Common clinical variables predict warfarin maintenance dose and therapeutic resistance. *Journal of Thrombosis and Thrombolysis*, **2008**, 25, 101-101	5.1	
21	Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura. *Blood*, **2020**, 136, 8-9	2.2	
20	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. *Blood*, **2021**, 138, 2080-2080	2.2	
19	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. *Blood*, **2021**, 138, 3039-3039	2.2	
18	Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies. *Blood*, **2021**, 138, 769-769	2.2	
17	Cyclosporine Alone for the Treatment of Early Recurrences of TTP.. *Blood*, **2005**, 106, 1236-1236	2.2	
16	A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry.. *Blood*, **2005**, 106, 2660-2660	2.2	
15	Evaluation of Qualitative Platelet Disorders in Patients with Hemophilia.. *Blood*, **2005**, 106, 3987-3987	2.2	
14	Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease.. *Blood*, **2005**, 106, 3180-3180	2.2	
13	Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.. *Blood*, **2005**, 106, 1235-1235	2.2	
12	Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.. *Blood*, **2007**, 110, 4018-4018	2.2	
11	Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD). *Blood*, **2018**, 132, 4572-4572	2.2	
10	A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura. *Blood*, **2019**, 134, 2377-2377	2.2	
9	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. *Blood*, **2019**, 134, 2366-2366	2.2	

8	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. *Blood*, **2019**, 134, 1093-1093	2.2
7	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. *Blood*, **2019**, 134, 1066-1066	2.2
6	Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.. *Blood*, **2008**, 112, 2299-2299	2.2
5	Comparison of Clinical Outcomes Between Initial and Relapsed Events of Thrombotic Thrombocytopenic Purpura In a Large TTP Cohort.. *Blood*, **2010**, 116, 1439-1439	2.2
4	Longitudinal Analysis of VWF Multimerization Patterns In a well-defined TTP Cohort. *Blood*, **2010**, 116, 4308-4308	2.2
3	Diagnostic and Prognostic Values Of ADAMTS13 Activity Measured During Daily Plasma Exchange Therapy In Patients With Acquired TTP. *Blood*, **2013**, 122, 1079-1079	2.2
2	Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS. *Blood*, **2013**, 122, 3552-3552	2.2
1	Recent advances in the management of atypical hemolytic uremic syndrome. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 537-9	0.6